SR9011: A Higher-CNS-Penetrant Rev-ErbA Agonist
SR9011 is a Rev-Erbα/β agonist structurally related to SR9009, but with a reported higher degree of CNS penetration. Both compounds activate Rev-Erb receptors and produce overlapping metabolic effects in animal models, but SR9011’s brain access makes it particularly valuable for research examining circadian disruption, anxiety, and neurological aspects of metabolic dysregulation that SR9009 cannot fully address due to its more limited CNS bioavailability.
Metabolic Effects: What the Data Shows
In rodent studies, SR9011 increases energy expenditure, reduces body fat, improves cholesterol profiles, and enhances exercise capacity — effects highly consistent with SR9009. The proposed mechanism involves the same Rev-Erb-mediated repression of lipogenic gene expression and upregulation of mitochondrial biogenesis. At equivalent molar doses in cell-based assays, SR9011 shows EC50 values of approximately 790 nM (α) and 560 nM (β), making it somewhat less potent than SR9009 per unit concentration but potentially more effective in CNS tissues due to penetration advantages.
SR9011 in CNS Research Designs
The most compelling differentiated use case for SR9011 over SR9009 is in studies with a neurological or circadian component — anxiety models, sleep research, cognitive function studies, and research into Rev-Erb expression in the brain. Studies have shown that SR9011 reduces anxiety-like behaviors in rodents via central Rev-Erb activation, an effect not reliably replicated with SR9009. For pure peripheral metabolic studies, the two compounds are largely interchangeable, though SR9009 has more published dose-response data for such applications.
Companion Compounds in Panel Studies
SR9011 is commonly studied alongside SR9009 to establish tissue distribution comparisons, and alongside PPARδ agonists like GW501516 and GW0742 for metabolic panel work. In nootropics-adjacent research, SR9011’s CNS effects are sometimes compared with those of cognitive compounds like Noopept or NSI-189, which target entirely different neurological pathways.
Available Research Formulations
See also: SR9009 Research Guide. For laboratory research use only.
